GSK Head Sees Malaria Vaccine Filing In Year, Says Go With Flow In India
This article was originally published in PharmAsia News
Executive Summary
After 30 years of trying, GlaxoSmithKline expects to have a malaria vaccine ready for filing by the end of next year, the long effort to end up selling at cost in emerging markets and elsewhere, CEO Andrew Witty says.